Showing results (1-10 of 198) with videos related to

Sort By:
Pageof 20
Gastroenterology|January 1, 1996
Therapeutics and inflammatory bowel disease: a guide to the interpretation of randomized controlled trialsB G Feagan, J W McDonald, J J Koval
The Cochrane Database of Systematic Reviews|January 22, 2003
Methotrexate for induction of remission in refractory Crohn's diseaseA A Alfadhli, J W McDonald, B G Feagan
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|December 13, 1997
Intravenous cyclosporine for severe attacks of ulcerative colitis: a survey of Canadian gastroenterologistsK A Atkinson, J W McDonald, B Lamba, et al.
Inflammatory Bowel Diseases|January 4, 2013
An evaluation of utility measurement in Crohn's diseaseJ C Gregor, J W McDonald, N Klar, et al.
Alimentary Pharmacology & Therapeutics|December 22, 1999
Review article: economic issues in Crohn's disease--assessing the effects of new treatments on health-related quality of lifeB G Feagan
Inflammatory Bowel Diseases|January 4, 2013
Cyclosporine has no proven role as a therapy for Crohn's diseaseB G Feagan
Pharmacotherapy|July 12, 2001
A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing LevofloxacinB G Feagan
Alimentary Pharmacology & Therapeutics|August 5, 2003
Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithmW J Sandborn, B G Feagan
The New England Journal of Medicine|June 30, 1994
Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial InvestigatorsB G Feagan, J W McDonald, J Rochon, et al.
Alimentary Pharmacology & Therapeutics|February 19, 1998
Review article: Drug development in inflammatory bowel disease: budesonide--a model of targeted therapyR Hamedani, R D Feldman, B G Feagan
Pageof 20